BioCentury | Sep 21, 1998
Company News
Cytogen cancer, diagnostics/imaging news
...CYTO ceased operations at its Cellcor Inc. subsidiary, which was developing its autologous lymphocyte therapy (ALT) to...
...carcinoma. CYTO had been in discussions concerning either a management buyout or other sale of Cellcor...
...BioCentury, March 30). CYTO reduced its workforce by 37 employees, including the 23 involved in Cellcor...
...carcinoma. CYTO had been in discussions concerning either a management buyout or other sale of Cellcor...
...BioCentury, March 30). CYTO reduced its workforce by 37 employees, including the 23 involved in Cellcor...